Which Tyrosine Kinase Inhibitor Must We Apply Before? A Case Report of Crizotinib-resistant Patient with Concomitant EGFR and EML4-ALK Gene Mutations
West Indian med. j
;
69(3): 148-153, 2021. graf
Artículo
en Inglés
| LILACS
| ID: biblio-1341890
ABSTRACT
ABSTRACT The concomitant epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) translocations in lung adenocancers are very rare scenarios. Until now, 42 cases described in the literature have all been treated by different drugs. There is no overall consensus regarding the treatment for this adenocarcinoma subgroup. We report here a case of lung adenocarcinoma with concomitant EGFR mutation in exon 21 (L858R) and ALK rearrangement in primary tumour, EGFR mutation in exon 21 (L858R) and no ALK rearrangement in its synchronous metastasis. We treated this patient with crizotinib as the second-line therapy (after the first line docetaxel-cisplatin chemotherapy), but no response was obtained. The therapeutic choice for the lung adenocancer patients with concomitant EGFR mutation and ALK rearrangement is unclear. Examination of c-ros oncogene 1 mutation can be used as an indicator in the prediction of the crizotinib treatment success. The ALK mutation may not responsible for the resistance to EGFR-tyrosine kinase inhibitors (TKI), and EGFR-TKI can be initiated to EGFR and ALK dual mutant patients as the first treatment.
Texto completo:
Disponible
Índice:
LILACS (Américas)
Asunto principal:
Adenocarcinoma
/
Genes erbB-1
/
Neoplasias Pulmonares
/
Mutación
Tipo de estudio:
Estudio pronóstico
Límite:
Femenino
/
Humanos
Idioma:
Inglés
Revista:
West Indian med. j
Asunto de la revista:
Medicina
Año:
2021
Tipo del documento:
Artículo
País de afiliación:
Turquía
Institución/País de afiliación:
Ege University/TR
/
Gazi University/TR
/
Medicana International Ankara Hospital/TR
/
Mugla Sitki Koçman University/TR
/
Sifa University/TR
Similares
MEDLINE
...
LILACS
LIS